Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense
This article was originally published in The Pink Sheet Daily
Executive Summary
Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.
You may also be interested in...
Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint
CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.
Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint
CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.
Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007
Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.